Effects of β3-adrenoceptor agonist on acute urinary retention in a rat model

Tae Il Noh1, Ji Sung Shim1, Sung Gu Kang1

  • 1Department of Urology, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul, 02841, Korea.

Abstract

Insights

Mirabegron demonstrated a protective effect in rats with acute urinary retention by improving bladder blood flow recovery. This treatment aided in restoring bladder tissue function following urinary retention.

Area of Science:

  • Urology
  • Pharmacology
  • Physiology

Background:

  • Acute urinary retention (AUR) can lead to bladder dysfunction.
  • Understanding the mechanisms and potential treatments for bladder protection during AUR is crucial.

Purpose of the Study:

  • To investigate the protective effects of mirabegron on bladder dysfunction in an acute urinary retention rat model.
  • To assess mirabegron's impact on bladder blood flow, nitric oxide levels, and tissue histology.

Main Methods:

  • Thirty-six rats were divided into mirabegron and normal saline (N/S) groups.
  • Bladder blood flow was measured using laser Doppler, and nitric oxide (NO) levels were assessed.
  • Histopathological examination of bladder tissue was performed at 30 minutes, 2 hours, and 24 hours.

Main Results:

  • Mirabegron significantly enhanced and accelerated bladder blood flow recovery compared to N/S.
  • NO levels were higher in the mirabegron group, though not statistically significant.
  • Histological analysis showed near-normal bladder tissue in the mirabegron group after 24 hours.

Conclusions:

  • Mirabegron demonstrates a protective and restorative effect in an acute urinary retention rat model.
  • The drug helps maintain and restore bladder blood flow, mitigating dysfunction.
  • These findings suggest mirabegron's potential therapeutic value in managing conditions associated with acute urinary retention.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.2K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.8K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.5K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.2K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.0K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.3K